Sri Lanka's improvements in healthcare have created stronger commercial opportunities for drug makers in the country,which is also experiencing an epidemiological shift towards chronic diseases.
However, strong reliance on foreign aid as well as medicine price caps will limit increases in revenue earning opportunities, Sri Lanka Pharmaceuticals and Healthcare Report Q1 2015 of the Business Monitor International (BMI) says.
According to the report, Sri Lanka's Pharmaceutical Risk/Reward Index (RRI) score for Q1 2015 stands at 38.2 out of 100, making it the 17th most attractive pharmaceutical market in the Asia Pacific region.
In 2013 Sri Lanka has spent Rs. 67.7 billion (US$ 524 million) for pharmaceuticals and Rs. 75.09 billion (US$ 570 million) in 2014. For Healthcare in 2013 Sri Lanka has spent Rs. 261.04 billion (US$ 2.02 billion).
The amount has increased to Rs. 283.97 billion (US$ 2.16 billion) in 2014.
www.dailynews.lk
However, strong reliance on foreign aid as well as medicine price caps will limit increases in revenue earning opportunities, Sri Lanka Pharmaceuticals and Healthcare Report Q1 2015 of the Business Monitor International (BMI) says.
According to the report, Sri Lanka's Pharmaceutical Risk/Reward Index (RRI) score for Q1 2015 stands at 38.2 out of 100, making it the 17th most attractive pharmaceutical market in the Asia Pacific region.
In 2013 Sri Lanka has spent Rs. 67.7 billion (US$ 524 million) for pharmaceuticals and Rs. 75.09 billion (US$ 570 million) in 2014. For Healthcare in 2013 Sri Lanka has spent Rs. 261.04 billion (US$ 2.02 billion).
The amount has increased to Rs. 283.97 billion (US$ 2.16 billion) in 2014.
www.dailynews.lk
No comments:
Post a Comment